Trials / Completed
CompletedNCT00954356
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction
Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Safety, PK, & Efficacy of a Single Oral Dose of XPF-001 in the Treatment of Pain Related to Third Molar/Wisdom Tooth Extraction.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Xenon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XPF-001 | Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules) |
| DRUG | placebo | Single oral administration of 5 x 100 mg Placebo capsules. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2009-11-01
- Completion
- 2009-12-01
- First posted
- 2009-08-07
- Last updated
- 2012-07-16
- Results posted
- 2012-06-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00954356. Inclusion in this directory is not an endorsement.